Navigation Links
Sanofi Pasteur Presents Positive Results of Tetravalent Dengue Candidate Vaccine
Date:11/6/2007

LYON, France, November 6 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today positive results in the development of a vaccine for the global prevention of dengue fever, one of the most widespread tropical diseases. The results are being presented today at the American Society of Tropical Medicine and Hygiene (ASTMH)'s 56th annual meeting held in Philadelphia, Pennsylvania, USA.

These results have prompted Sanofi Pasteur to immediately expand ongoing clinical trials in Asia and Latin America. Submission to health authorities for registration is anticipated in 2012.

"Sanofi Pasteur made research for a vaccine against dengue fever one of its top priorities by investing in the most promising technology and dedicating top scientists to this lifesaving project," said Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur. "Sanofi Pasteur's goal is to make dengue fever a vaccine-preventable disease as quickly as possible with a vaccine available to people living in endemic countries or traveling to tropical destinations."

Immunization with Sanofi Pasteur's tetravalent dengue candidate vaccine generated a sero-neutralizing antibody response against all four serotypes of the virus responsible for dengue fever in 100 percent of adults who participated in a trial in the United States.(1)

"Developing a dengue vaccine has been a major challenge for over a decade, and we are very pleased with the breakthrough progress made by Sanofi Pasteur with its tetravalent dengue vaccine," said Harold Margolis, MD, Director of the Pediatric Dengue Vaccine Initiative (PDVI). "We believe this moves the world closer to a dengue vaccine that will be available for people who most need it."

Dengue fever is a mosquito-borne disease affecting up to 100 million people each year and resulting in 24,000 deaths, mostly among children, according to estimates from the World Health Organization (WHO).(2
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
2. Sanofi-aventis US Chairman Tim Rothwell Addresses CMSAs Collaborative Practice Summit
3. Sanofi Pasteur and Institut Pasteur Team up Against Malaria
4. Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
5. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
6. The Art Of Maternity(TM) at Destination Maternity(R) Presents A Sacred Passage Into Motherhood; the Art of Belly Masking to Belly Casting
7. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
8. VNUS Medical Technologies Presents at William Blair Small-Cap Growth Stock Conference
9. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
10. Retirement Living TV Presents Sex, Drugs and Rock N Roll
11. AviaraDx Presents at 2007 BIOCOM Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... -- Klafter & Olsen LLP has filed a,class action l..." or the,"Company") (Nasdaq: ARTC ) and certain o...Western District of Texas on behalf of all persons...Care from January 24, 2008,through July 18, 2008 (...,persons or entities who purchased call options or...
(Date:7/25/2008)...etroviral therapy may be due to genetic factors ,...new study challenges the long-held belief that the...,s ability to restore itself after HIV patients ar...y (HAART). , From 50 percent to 90 percent of H... Intravenous drug use is the main cause of both ty...
(Date:7/25/2008)...BeaconEquity.com announces the,availability of Tra... can view all of the daily trading notes for free ... Trade Alerts include: DUSA Pharmaceuticals Inc. (...(Nasdaq: MBRK ), NovaMed Inc. (Nasdaq:,NOVA), Ado...q: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., Joi...
(Date:7/25/2008)...ificant Improvements in Members, Health, ATLANTA,... in health,care quality management solutions for h...entered into a long-term agreement with Wellmark, ...on on Quality(SM) Incent and,Reward Best Practices...primary care clinicians to promote improved qualit...
Breaking Medicine News(10 mins):Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3
...sociated with cancers, fibrosis and other diseases...say // exposure to asbestos may lay the groundwork... arthritis and multiple sclerosis. Researchers exa... known to be polluted by asbestos. They found thes...
... a frightening experience for children as they oft...ew study shows hypnosis could help reduce distress...re. The study included children who were schedule...y. During a VCUG, a tube is inserted into the blad...
...the poorer quality of life they will have, say res...children participated in the study . Researchers m...rt survey completed by a parent and child self-rep...otional, social and academic functioning of the ch...
...ween fast food consumption and weight gain and ins...eases the risk of obesity and type 2 diabetes. Res...rted fast food habits and changes in bodyweight an...ears. The diets of more than 3,000 young adults we...
Other Medicine News:
(Date:7/22/2008)...ility and Efficacy of Treating Patients with ...NCISCO, and YONGIN-SI, South Korea, July 22 /PRNew...tawa, Ontario), and its South,Korean partner Green...from,a Phase I clinical trial of its first-in-clas...t was well-tolerated and resulted in clear,anti-ca...
(Date:7/22/2008)...tress the Importance to Patients of Passing a ... RICHMOND, Va., July 22 /-...ow-on biologics and biopharmaceuticals, today,anno...ill present at a,Congressional briefing on Friday,...or establishing an approval pathway for follow-on,...
(Date:7/22/2008)... by Columbia University Medical Center Based on ...hnology, The Test Differentiates Squamous From N...lassifying Squamous-Cell Carcinoma of the Lung Wit... of 90 Percent,This is the First CLIA Approved Tes...as Biomarkers for Accurate Diagnosis of Lung Cance...
(Date:7/22/2008)...idual,s Genetic Risk Based on Clinical Data, Pr...al Materials, WALTHAM, Mass., July 22 /PRNewswire...ILI ), today announced the launch of an enhanced t...company,s Heart Health Genetic Test.,The test is c...Heart Health,Genetic Test by Quixtar/Amway. The ne...
Breaking Medicine Technology:Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Researchers successfully simulate photosynthesis and design a better leaf 1169 1Researchers successfully simulate photosynthesis and design a better leaf 1169 2Researchers successfully simulate photosynthesis and design a better leaf 1169 3Abnormal immune cells may cause unprovoked anaphylaxis 5990 1Abnormal immune cells may cause unprovoked anaphylaxis 5990 2Abnormal immune cells may cause unprovoked anaphylaxis 5990 3Research highlights important indicators of early stage ovarian cancer 5988 1New technology illuminates protein interactions in living cells 1167 1New technology illuminates protein interactions in living cells 1167 2
...ion Therapeutics,announced today that data on two ...prednate) and ST-602 (fenretinide), will be,presen...for,Research in Vision and Ophthalmology (ARVO) in...tions, the company will be hosting a,reception for...ntly being evaluated in two phase,III clinical tri...
...erlying Cause of,Genetic Disorders and Restores Pr...2007 /PRNewswire/ -- New,preclinical data publishe...ure show that PTC124, an investigational new drug,...ious in a,preclinical model of Duchenne muscular d... 13 percent of the cases of DMD are due,to nonsens...
Other Medicine Technology:Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 2Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 3Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 4Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 2Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 3Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 4
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability.
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability.
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability.
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available.
Medicine Products: